2011至2015年外科主动脉瓣置换术实践与结局趋势:德国主动脉瓣注册研究42 776例患者更新
基于德国主动脉瓣注册研究42 776例2011至2015年行外科主动脉瓣置换术(伴或不伴冠状动脉旁路移植)患者,分析患者选择、手术特征与短期结局。结果显示院内死亡率2.3%,致残性卒中1.3%,残余主动脉瓣反流≥2°0.4%,新发起搏器/植入式心律转复除颤器植入3.9%。
要点
- 单纯外科主动脉瓣置换术占62.2%(26 618例),联合冠状动脉旁路移植占37.8%(16 158例)。
- 2011至2015年STS预测死亡风险从2.4%降至2.2%(P < 0.001),合并风险因素比例下降。
- 65岁以下患者生物瓣使用率从50.1%升至65.7%(P < 0.001),快速释放瓣膜比例从1.5%升至8.4%(P < 0.001)。
核心结论
- 基于2011至2015年超过42 000例患者,单纯外科主动脉瓣置换术及联合冠状动脉旁路移植均获得优异的院内结局。
- 替代治疗策略的实施使患者和设备选择发生了明显变化。
研究设计与样本
- 分析德国主动脉瓣注册研究中42 776例2011至2015年接受外科主动脉瓣置换术伴或不伴冠状动脉旁路移植的患者数据。
- 分析基线、手术特征及短期结局参数。
主要发现
- 全部注册患者中,26 618例(62.2%)接受单纯外科主动脉瓣置换术,16 158例(37.8%)接受外科主动脉瓣置换术联合冠状动脉旁路移植。
- 中位年龄72岁,中位STS预测死亡风险(STS PROM)为2.3%。
- 2011至2015年STS PROM从2.4%降至2.2%(P < 0.001),肺动脉高压从9.1%降至3.2%(P < 0.001),闭塞性动脉疾病从19.6%降至17.7%(P = 0.003),二尖瓣反流≥2°从10.6%降至7.6%(P < 0.001),纽约心脏协会心功能III/IV级从65.3%降至59.2%(P < 0.001)。
- 院内死亡率为2.3%,致残性卒中1.3%,残余主动脉瓣反流≥2°0.4%,新发起搏器/植入式心律转复除颤器植入3.9%。
- 65岁以下患者生物瓣使用率从50.1%升至65.7%(P < 0.001),快速释放瓣膜比例从1.5%升至8.4%(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Surgical aortic valve replacement (sAVR) is coming under close scrutiny with the recent upswing in the use of less invasive approaches. The aim of this analysis was to identify current trends in patient selection, procedural characteristics and outcomes after sAVR in Germany. METHODS: We analysed data from 42 776 patients included in the German Aortic Valve Registry who underwent sAVR with and without coronary artery bypass surgery (CABG) between 2011 and 2015. Baseline, procedural and short-term outcome parameters were analysed. RESULTS: Of all registered patients, 26 618 (62.2%) underwent isolated sAVR and 16 158 (37.8%) sAVR + CABG. The median age was 72 years, and the median Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) was 2.3%. From 2011 to 2015, there was a decline in STS PROM (2.4-2.2%, P < 0.001) and a decline in risk factors, such as pulmonary hypertension (9.1-3.2%, P < 0.001), occlusive arterial disease (19.6-17.7%, P = 0.003), mitral regurgitation ≥2° (10.6-7.6%, P < 0.001) and New York Heart Association Class III/IV (65.3-59.2%, P < 0.001). In-hospital mortality was 2.3%, 1.3% had disabling stroke, 0.4% residual aortic regurgitation ≥2°, and the incidence of new-onset pacemaker/implantable cardioverter-defibrillator implantation was 3.9%. There was an increase in the use of biological valves in patients <65 years (50.1-65.7%, P < 0.001), and the proportion of rapid deployment valves increased significantly (1.5-8.4%, P < 0.001) over the investigated time period. CONCLUSIONS: Both isolated sAVR as well as sAVR + CABG resulted in excellent in-hospital outcomes based on >42 000 patients treated between 2011 and 2015. The implementation of alternative treatment strategies has resulted in palpable changes in patient and device selection.
引用
- Fujita B, Ensminger S, Bauer T, et al. Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42 776 patients. Eur J Cardiothorac Surg. 2018. PMID: 29190355. doi:10.1093/ejcts/ezx408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。